Since inactivation and loss of PTEN, and overexpression of AKT are frequently observed in pancreatic cancer [14], targeting a downstream target such as FOXO may be an attractive idea for pancreatic cancer prevention and/or treatment. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.